DelveInsight's Nontuberculous Mycobacterial Infection Market Insights report includes a comprehensive understanding of ...

Mpox: a disease at our doorstep - the latest health concerns, including India’s first mpox case, and what it means for the ...

The union government has approved a shorter and more effective treatment regimen for multi-drug-resistant tuberculosis. This ...

Mumbai: Ahead of the rollout of the shortest treatment for drug-resistant TB, called BPaL, Indian doctors published a study proving that halving the d.

This regimen includes a new anti-TB drug namely Pretomanid in combination with Bedaquiline & Linezolid (with/without ...

moxifloxacin, norfloxacin or ofloxacin Antidepressants such as citalopram, fluoxetine, fluvoxamine, venlafaxine, paroxetine ...

This regimen includes a new anti-TB drug, namely Pretomanid, in combination with Bedaquiline & Linezolid (with/without Moxifloxacin). Pretomanid has earlier been approved and licenced for use in India ...

THE Union Health Ministry has approved the introduction of the BPaLM regimen, a novel treatment for multi-drug resistant ...

Key aspects of the BPaLM regimen: Composition: The regimen combines four drugs—Bedaquiline, Pretomanid, Linezolid, and ...

India's fight against Multi-Drug-Resistant Tuberculosis (MDR-TB) has received new ammunition with the Centre giving nod for the shorter and safer BPaLM regimen (bedaquiline, pretomanid, linezolid, and ...

It combines Pretomanid, a recently approved anti-TB drug by the Central Drugs Standard Control Organization (CDSCO), with ...

Move expected to significantly boost progress towards the national goal of Ending TB in India ...